Hengrui Pharma Co.,Ltd’s Post

Exciting news from the ESMO Sarcoma and Rare Cancers Congress 2024! Promising results from the PM1183-A-014-15 study suggest a synergistic clinical effect of lurbinectedin and irinotecan in pre-treated Grade 3 gastroenteropancreatic neuroendocrine carcinomas. The Phase II study reports ORR of 15%, DCR of 60%, median PFS of 3.1 months & OS at 12 months of 45.0%. This combination therapy shows potential as a novel regimen for patients who have failed prior platinum-based therapies. 👉https://ow.ly/QASy50QVjmx #MedEd

ASCO 2024: Nivolumab and ipilimumab combination preparing to enter the first-line hepatocellular carcinoma realm. Bristol Myers Squibb recently revealed that first-line treatment with nivolumab and ipilimumab significantly improved overall survival in patients with advanced hepatocellular carcinoma compared to sorafenib or lenvatinib, successfully meeting the trial's primary endpoint. The interim analysis confirmed that the combination has a manageable safety profile, consistent with previous data, and no new safety concerns were identified. These latest findings, set to be presented at the upcoming ASCO meeting, highlight the combination’s efficacy and competitive potential in treating this condition. Get detailed coverage on Hepatocellular Carcinoma treatment, visit: https://lnkd.in/gyv23vVt #BristolMyersSquibb #Nivolumab #Ipilimumab #HepatocellularCarcinoma #CancerTreatment #SurvivalImprovement #ClinicalTrials #ASCO2024 #Oncology #MedicalResearch #CancerBreakthrough #Immunotherapy #LiverCancer #PharmaNews #HealthcareInnovation

Our last paper —>The best therapeutic sequence in patients with advanced stage hepatocellular carcinoma treated with first-line immunotherapy remains unanswered to this day. We have attempted to provide an answer with real-world data, investigating whether there is a difference in using lenvatinib or sorafenib in patients who have progressed on atezolizumab plus bevacizumab. Here the work. https://lnkd.in/ezGkFbJR

The correct choice of systemic therapy for unresectable hepatocellular carcinoma could be challenging due to the variability of the response to treatment! In this scenario fits our Editorial entitled "Tislelizumab: a promising alternative first-line systemic therapy in unresectable advanced hepatocellular carcinoma" that briefly describes the different first-line therapeutic opportunities, includingTislelizumab, a new emerging and promising drug in this field. Now available online: https://lnkd.in/d_ev9gjJ Enjoy your reading! #hepatocellularcarcinoma #hcc #livercancer #immunotherapy #studyliver

Can More Than 6 Cycles of LuPSMA Therapy Be Administered Safely in mCRPC? 🚀Exciting news from our recent German multicenter trial! We investigated the safety and efficacy of extended LuPSMA therapy in mCRPC patients across Essen, Munich, Augsburg, and Münster. Here’s what we found: - Safety: Patients receiving more than 6 cycles of LuPSMA therapy had low rates of severe (grade 3/4) toxicities. - Efficacy: Median overall survival for extended treatment reached a promising 31 months. - Rechallenge treatment: Pausing and resuming LuPSMA therapy resulted in a lower 50% PSA response rate compared with the initial response (37% vs. 90%), but achieved a median overall survival of 40 months. While this retrospective analysis of 111 patients is promising, prospective studies are needed to confirm these findings. This concept could potentially be applied to earlier stages of prostate cancer as well. 🔗Read the full publication and explore the details: https://lnkd.in/eSrUVsvD https://lnkd.in/eF5DKq3Z

📊 Amador Study Share 📊 Excited to share an Amador-involved study presented at ASCPT 2024. The poster focuses on #PopPK modeling of Camrelizumab in patients with various cancers, including advanced hepatocellular carcinoma. Through modeling PK data from 10 clinical studies, including the Phase III pivotal trial, the PK model showed that: 🔹 Exposure was generally proportional to dose over a 200-600 mg dose range. 🔹 Median time to >90% of steady-state exposure (AUC) was estimated as ~16 weeks following the start of camrelizumab 200 mg Q2W dosing. 🔹 The model estimated 2.3-fold accumulation from the first dose to steady-state. 🔹 An effective half-life based on the model-predicted accumulation ratio was estimated as ~17 days. 🔔 Learn more, please click https://lnkd.in/gZgfXnxw #Pharmacokinetics #Camrelizumab #ASCPT2024 #DrugDevelopment #AmadorBio #Innovation

Read Dr. Joshua Richter’s article on measurable residual disease (MRD) testing in the community oncology setting: https://clonoseq.co/nu9. This article covers how to use highly sensitive MRD assessment methods, such as clonoSEQ—which can detect MRD at a threshold of 10-6, given sufficient sample input, to gain critical insights to help guide your approach for lymphoid malignancy patients. FDA-cleared to measure MRD in MM, CLL, & ALL; CLIA-validated in other lymphoid cancers. Info on sample types & test limitations: https://rb.gy/8tju9y

GPC3-targeting NK Engager bispecific antibody, as a monotherapy for the treatment of hepatocellular carcinoma in patients not responding to first-line immunotherapy. https://lnkd.in/d8nPEMrZ

#Ribociclib was approved by the FDA for stage II/III ER+ breast cancer in the adjuvant setting in combination with endocrine therapy. This is 2nd CDK4/6 inhibitor in the setting ! Very small benefit shows 5% improvement in DFS at 4 yrs. The differences compared to abemcicilib: 📍3 year duration vs. 2 yrs 📍intermittent 3 weeks on, 1 off, not continuous 📍includes more patients including some with node negative disease 📍less diarrhea than abema, but more neutropenia 📍need for ECG ❤️ monitoring at baseline and at day 15 (cycle 2 ECG no longer needed unless risk factors), need for LFT monitoring (this isn't an insignificant % of pts and needs to be closely watched 👀 ) 📍Lower dose of ribo in adjuvant setting (400mg vs. 600 mg in metastatic, abema dose is the same across early and metastatic) Update was presented #ESMO24 just this week and shows 5% improvement in DFS at 4 yrs. just like #abema the benefit has increased every time we look at updated data.

Honored to participate from AdventHealth Central Florida #cancer Institute with colleagues Vadim Koshkin Petros Grivas, Karine Tawagi, Terry Friedlander in this GU Oncology Now roundtable discussion of all things #bladdercancer #urothelialcarcinoma on the heels of #GU24: 1) New data supporting adjuvant pembrolizumab for high-risk muscle-invasive #urothelialcarcinoma Andrea Apolo, 2) Emerging new agents & combinations- Pembrolizumab + Cabozantinib Rohit Jain, EV + Erdafitinib Rohit Jain, Datopotamab Deruxtecan, 3) Firstline therapy of metastatic disease- EV-pembro vs. GC-nivo vs Javelin paradigm as firstline therapy for advanced #urothelialcarcinoma #bladdercancer: EV (enfortumab vedotin)-pembro for most patients, but consider GC-nivo (once hopefully approved) for cisplatin-eligible patients with node-only disease (need #precisionmedicine, molecular biomarkers ?ERCC2 mutations) given curative potential of GC (gemcitabine-cisplatin) in this setting and highly durable CRs (median ~37 months) with GC-nivo; Javelin paradigm (platinum-combination-> avelumab) remains an option for cisplatin-ineligible patients unfit for EV-pembro, 4) Role of erdafitinib in advanced disease with FGFR3 activating genomic alterations